Olink Proteomics

Company details

Year Aquired

2019

Location

Uppsala, Sweden

Revenue (2021)

859 m

Sector

Life Science

Employees

416

Investment Themes

Changing Demographics

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Olink at a glance

Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This enables research which previously could not be done and lowers costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease.


Key developments in 2021

In March 2021, Olink was listed on the US Nasdaq at $20/sh. Since the IPO of Olink, the company has significantly improved its operational and organizational capabilities, roughly doubling the size of the organization in 2021. Despite COVID-19 related supply chain frictions in 3Q21, the company met or outperformed guidance on their key KPIs for the year, including 25 Explore externalizations, 28 Signature placements and 100% coverage of the plasma proteome with the Explore 3072. Full year 2021 revenue was $95MM, beating consensus estimates and representing a 76% yoy growth.

Impact dimensions

The challenges we face

We currently suffer from ineffective medication due to a lack of understanding of the biology of diseases. The shift from the "one size fits all" approach to precision medicine is a colossal challenge for science. Delivering the right treatment, to the right patient at the appropriate time requires developing protein biomarker panels to improve our understanding of human biology and optimize the development of new drugs and treatments.

 

%
is the expected proportion of people aged 80 or above in the year 2070, up from 4.9% in 2016.
%
share of GDP spent on healthcare in the OECD

 

What is the outcome?

Olink contributes to the understanding of the human biology through its unique technology aimed at science related to proteomics. Olink’s approach enables science that was not previously possible, and is a key contributor to precision medicine.


Who are the stakeholders?

Olink's customers are primarily found in pharma and in academic centers.


How big is the effect, and does it last?

Olink, with a library of over 2 947 validated biomarker assays, has been mentioned in 791 publications, supporting protein biomarker discovery research globally. Enabling precision medicine is important to drive better patient outcomes and sustainable costs in healthcare systems over time.


If Olink didn’t exist…

Since Olink provides a truly unique technology to the market, it makes a great contribution to precision medicine. If Olink did not exist, a vast majority of the research that it enables would not get done.


Impact risk: what can go wrong?

Product quality is fundamentally important, so if Olink would be unable to deliver strong product quality, its customers would likely stop using its products.

Year Aquired

2019

Revenue (2021)

859 m

Employees

416

Investment Themes

Changing Demographics

Sector

Life Science

Location

Uppsala, Sweden

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Website

Video

SDG Alignment
SDG Wheel
SDG 3
KPI reporting
SDG 8

REVENUE (SEKm)

2021
+76%
869
2020
489
2019
404
SDG 3

NO. OF PROTEIN DATA POINTS GENERATED

2021
252%
881 m
2020
250m
2019
151m
SDG 13

NUMBER OF PUBLICATIONS

2021
+58%
791
2019
343
2018
221

Learn more about Olink

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its…

Read the story

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to…

Read the story

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its...
Learn more

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to...
Learn more